1. Introduction {#sec1-cancers-12-00527}
===============

1.1. Background {#sec1dot1-cancers-12-00527}
---------------

In our society, cancer is an increasingly prevalent and therapeutically challenging disease. Of all cancer patients treated curatively, half will receive radiation therapy \[[@B1-cancers-12-00527]\]. However, despite these efforts, more than a quarter of a million people die from cancer in the EU annually \[[@B2-cancers-12-00527]\]. The main factor limiting conventional radiotherapy (RT) is the toxicity induced in vital surrounding healthy tissues, which constrains dose-escalation and effective tumour control \[[@B3-cancers-12-00527]\]. Synchrotron X-ray microbeams have been recognized as a unique tool to overcome this limitation \[[@B4-cancers-12-00527]\], eliciting scientific interest across the world in a radio-therapeutic application known as Microbeam Radiation Therapy (MRT). MRT consists of a spatially-modulated, co-planar array of low energy X-rays delivered to tumours \[[@B5-cancers-12-00527]\]. These spatially fractionated beams exploit the dose-volume effect for extraordinary normal tissue tolerance \[[@B6-cancers-12-00527]\] and trigger a cascade of biological effects that greatly improve tumour control \[[@B7-cancers-12-00527]\].

1.2. Rationale {#sec1dot2-cancers-12-00527}
--------------

In the last few decades, MRT research has expanded to include several synchrotron and non-synchrotron sources around the world. The progress, however, has been relatively slow. A significant challenge for MRT is the wide range of modifiable radiation parameters which can profoundly impact its radiobiological effects, and ultimately, treatment outcomes. Research groups have explored these radiation parameters using various rodent and non-rodent animal models. However, there remains no clear consensus within the community on the optimal MRT parameters and strategy for cancer therapy, delaying translation to human clinical trials. Comprehensively evaluating the existing literature is essential to unifying these pre-clinical data and strategically promoting future research to support clinical translation.

1.3. Objective {#sec1dot3-cancers-12-00527}
--------------

The objective of this scoping review is to map the available evidence and provide an overview of the similarities, differences, and outcomes of all experiments that have employed animal models in MRT. The aim is to inform the community about progress made in the field of MRT and to identify existing gaps in current research.

2. Methods {#sec2-cancers-12-00527}
==========

2.1. Protocol and Registration {#sec2dot1-cancers-12-00527}
------------------------------

Our protocol was developed according to the scoping review methodological framework proposed by the Joanna Briggs Institute \[[@B8-cancers-12-00527]\], and refined by two methodological papers on how to conduct scoping reviews published by Peters at al. \[[@B9-cancers-12-00527]\] and Tricco et al. \[[@B10-cancers-12-00527]\]. The draft protocol was revised by the research team of the Institute of Anatomy of the University of Bern and by the information specialist of the University of Bern's Medical Library. The protocol could not be registered in the International Prospective Register of Systematic Reviews (PROSPERO), as this is not yet an option for scoping reviews. This scoping review was written according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-update for Scoping Reviews \[[@B11-cancers-12-00527]\].

2.2. Eligibility Criteria {#sec2dot2-cancers-12-00527}
-------------------------

The review considered articles that employed animal models with the purpose of studying the normal tissue or therapeutic effects of MRT. We included all papers that employed MRT as (i) an array of co-planar microbeams, (ii) from any radiation source (synchrotron and non-synchrotron) and quality (photons, protons, and others), (iii) that were applied to animals. We defined MRT as an array of co-planar microbeams of widths equal to or lower than 100 µm, which are spaced by a few hundred micrometres within the array. This definition of MRT has been used by other research groups, and it is becoming the standard in the field \[[@B5-cancers-12-00527],[@B12-cancers-12-00527],[@B13-cancers-12-00527],[@B14-cancers-12-00527],[@B15-cancers-12-00527]\]. MRT is also described as spatial fractionation of the radiation beam, which is the main difference with conventional radiotherapy ([Figure 1](#cancers-12-00527-f001){ref-type="fig"}). We excluded papers that employed minibeams because their width exceeds 100 µm. We also excluded publications that employed a single microbeam and a microbeam scanning technique because these approaches do not qualify as spatial fractionation.

2.3. Information Sources {#sec2dot3-cancers-12-00527}
------------------------

Literature searches were performed by an information specialist (HJ) in the following information sources: Medline (Ovid) (incl. Epub Ahead of Print, In-Process and Other Non-Indexed Citations, Medline Daily and Ovid Medline Versions (1946--October 02, 2019)Embase (Ovid) (1947--October 02, 2019)Cochrane Library (1996--October 02, 2019)Scopus (1788--October 02, 2019)ICTRP Trial Register (WHO)ClinicalTrials.govLivivo Search portal

2.4. Search Strategy {#sec2dot4-cancers-12-00527}
--------------------

An initial search strategy in Medline was drafted and tested against a list of core references to see if they were included in the search results. After refinement and consultation with the research team, search strategies were set up for each information source, based on database-specific, controlled vocabulary and text words. No limits have been applied in any database considering study types, languages, publication years, etc. Beside standard bibliographic databases for medical journals like Medline, Embase and the Cochrane Library, two interdisciplinary databases, Scopus and Livivo, have been selected to search for other publications types than journal articles (e.g., conference proceedings, book series, publications from university repositories). All searches were run on October 3rd, 2019. In addition to electronic database searching, bibliographies and reference lists from relevant publications were checked.

For our search strategy, we decided not to focus on any particular animal species or animal models. This allowed for maximum sensitivity in the search and ensured that publications on all organisms on which MRT had been applied were included in our search results. Therefore, our search strategy focused only on the concepts of "microbeam radiation therapy", "synchrotron x-ray microbeams" in combination with "radiotherapy", "therapy" or similar terms. The detailed search strategies are presented in [Supplementary Materials](#app1-cancers-12-00527){ref-type="app"}.

2.5. Selection of Sources of Evidence {#sec2dot5-cancers-12-00527}
-------------------------------------

All identified citations were collated, loaded into EndNote and duplicates were removed. The collection was then uploaded into the software Rayyan \[[@B16-cancers-12-00527]\]. Two independent reviewers performed the first level screening of titles and abstracts against the inclusion criteria. Two reviewers also performed the second level of full-text screening.

2.6. Data Charting and Synthesis of Results {#sec2dot6-cancers-12-00527}
-------------------------------------------

Three reviewers determined the variables to extract. The studies were charted jointly by using Microsoft Excel Online. We grouped the studies into experimental articles, reviews, clinical perspectives, reports, commentaries, and Letters to the Editor. Reviews, commentaries, and clinical perspectives were used to screen for possibly missing citations. The experimental articles and reports were charted.

3. Results {#sec3-cancers-12-00527}
==========

3.1. Literature Selection {#sec3dot1-cancers-12-00527}
-------------------------

After duplicates were removed, a total of 5688 records were identified ([Figure 2](#cancers-12-00527-f002){ref-type="fig"}). Based on title and abstract screening, 5534 citations were excluded, and 159 potentially relevant papers were assessed for full-text eligibility, which includes 5 additional records identified through reference scanning. After the full-text screening, 64 articles were further excluded, and 95 studies were finally included in the review. The list of included references can be found in the [Supplementary Materials](#app1-cancers-12-00527){ref-type="app"}.

3.2. Study Characteristics {#sec3dot2-cancers-12-00527}
--------------------------

The 95 papers studying animal models in MRT were disseminated between 1994 and 2019 ([Figure 3](#cancers-12-00527-f003){ref-type="fig"}A). The majority of the articles have been published in the last ten years, with the highest publication record (11 papers) in 2015. From the 72 experimental articles, the most commonly used animal models have been Rats (59.7%) and Mice (33.3%) with only a few studies using other animal models ([Figure 3](#cancers-12-00527-f003){ref-type="fig"}B).

3.3. Technical Parameters {#sec3dot3-cancers-12-00527}
-------------------------

In the reviewed literature, the MRT array was created via two mechanisms. By performing several consecutive irradiations (with horizontal translation) using a single-slit collimator, to generate an array of co-planar microbeams at the target. Alternatively, by using a multi-slit collimator that generates an array of co-planar microbeams simultaneously.

Across the included literature, the width of the microbeams ranged from 20 to 100 µm, with spacing varying from 50 up to 500µm (See [Table 1](#cancers-12-00527-t001){ref-type="table"}; [Table 2](#cancers-12-00527-t002){ref-type="table"}).

MRT can be delivered as a single or multiple array(s). When multiple arrays are delivered, the irradiation geometry can be subclassified according to the trajectory of delivery and the anatomical plane.

-   Trajectory of delivery: if two or more arrays were delivered in the same trajectory or direction, they were called unidirectional. However, if the arrays were delivered in two or more trajectories, they were referred to as bidirectional or multidirectional.

-   Anatomical plane: if two or more MRT arrays were delivered in the same anatomical plane they were also called co-planar. When two co-planar arrays were delivered without overlap of the peak-dose regions, they were referred to as interlaced. Delivery in different planes was referred to as cross-planar where irradiation with a single unidirectional MRT array was followed by a rotation of the animal and a second (or third) MRT array was delivered (creating a grid-like pattern in the target volume). When arrays in this manner intersect at 90°, they are orthogonal (irrespective of the anatomical plane or trajectory).

The use of the word cross-fired however, was more general. It described two or more arrays, but it did not inform consistently about the trajectory or the anatomical plane of the arrays.

Peak-doses ranged from 3.9 Gy \[[@B17-cancers-12-00527]\] up to 10000 Gy \[[@B18-cancers-12-00527]\], however, the depth at which they were measured varied across the publications from 0.3 mm (skin-entry or entrance) to several millimetres in depth depending on the location of the target. Valley-doses were also reported at different depths, the lowest was 0.5 Gy at skin-entry \[[@B19-cancers-12-00527]\], and the highest was 38.5 Gy at 5 mm depth \[[@B20-cancers-12-00527]\]. Additionally, the peak-to-valley dose ratio (PVDR) was described as an important metric related to the therapeutic index of MRT \[[@B21-cancers-12-00527]\].

Dose-rate was reported in only 27 out of 72 experimental articles and varied greatly from 0.3 to 16000 Gy/s. This large variation is relevant because dose-rate, together with the peak-dose, will determine whether MRT will also have a FLASH effect. The FLASH effect is defined as the delivery of radiation at ultra-high dose rates, which allows normal tissue tolerance levels to be exceeded \[[@B22-cancers-12-00527],[@B23-cancers-12-00527],[@B24-cancers-12-00527]\]. This is achieved when the whole dose of radiation (the peak-dose in the case of MRT) is delivered in less than 200 milliseconds \[[@B24-cancers-12-00527]\]. Therefore, not all MRT sources will be able to have a FLASH effect since, for example, the delivery of a peak-dose of 400 Gy requires a dose rate of 2000 Gy/s as a minimum to be delivered in 200 milliseconds.

3.4. Animal Models in MRT {#sec3dot4-cancers-12-00527}
-------------------------

Animal models are divided into their use for investigating tumour control, non-neoplastic diseases and normal tissue effects following MRT.

### 3.4.1. MRT for Cancer {#sec3dot4dot1-cancers-12-00527}

[Table 1](#cancers-12-00527-t001){ref-type="table"} reports all the studies that involve the use of MRT to treat tumour-bearing animals and summarises key radiation parameters which are associated with tumour control.

### 3.4.2. Glioma {#sec3dot4dot2-cancers-12-00527}

The most commonly employed cancer models in MRT research were brain tumours. The first animal model used was syngeneic 9L gliosarcoma (9LGS) implanted in rats. In the early nineties, at the National Synchrotron Light Source of the Brookhaven National Laboratory, Laissue, Slatkin and colleagues \[[@B25-cancers-12-00527],[@B26-cancers-12-00527],[@B27-cancers-12-00527],[@B28-cancers-12-00527]\] showed that MRT (unidirectional and bidirectional) delayed tumour growth of intracerebral 9LGS. Since then, 9LGS cells in the Fisher 344 strain rat model has been widely used to test several MRT configurations and doses.

In 2002, Dilmanian and colleagues \[[@B15-cancers-12-00527]\] studied different unidirectional arrays on the same 9LGS model. The array had a constant microbeam width (27 µm), three spacings (50 µm, 75 µm and 100 µm), and two peak-doses (150 Gy and 500 Gy). All MRT conditions improved survival as compared to the control group.

In addition, several studies conducted by Bouchet and colleagues \[[@B20-cancers-12-00527],[@B29-cancers-12-00527],[@B30-cancers-12-00527]\], using the 9LGS model, investigated the molecular mechanisms behind the MRT efficacy in comparison to unirradiated controls.

A comparison between a homogenous broad beam (BB) of radiation delivering 17.9 Gy to the tumour with one MRT array - formed by microbeams of 50 µm width and centre-to-centre spacing of 200 µm (hereafter defined as "50 µm; 200 ctc") - delivering 200 Gy peak-doses to the tumour revealed that the survival for the animals of both groups was similar \[[@B31-cancers-12-00527]\]. However, when the deposited peak-dose in the MRT array was increased to 400 Gy the survival of the gliosarcoma-bearing rats was significantly increased compared to the BB irradiated animals \[[@B31-cancers-12-00527]\].

Several studies have shown that delivering multiple MRT arrays increased the survival of 9LGS-bearing rats significantly compared with unirradiated controls \[[@B32-cancers-12-00527]\], with characteristic induction of hypoxia at the tumour site \[[@B33-cancers-12-00527]\]. Serduc et al. \[[@B34-cancers-12-00527]\] employed bidirectional MRT arrays to compare the efficacy of three different microbeams widths (25, 50 and 75 µm), each delivered as two orthogonally cross-planar intersecting arrays. In all the MRT configurations the valley-dose was kept constant (at 18 Gy each) by fixing the spacing (211 ctc), and only the peak-dose and the microbeam widths were modified. Thus, microbeams of 25, 50, and 75 µm of width, had peak-dose of 860 Gy, 480 Gy, and 320 Gy per array, respectively. All MRT groups delayed the 9LGS tumour growth. The bidirectional MRT of 50 µm 211 ctc had the best therapeutic index, while the bidirectional MRT of 25 µm, 211 ctc caused early deaths in 50% of cases four days after irradiation.

Three cross-planar MRT arrays (orthogonal to each other) were used to target 9LGS-bearing rats in three consecutive days at the European Synchrotron \[[@B35-cancers-12-00527]\]. Briefly, day 1 (25 µm; 211 ctc; 400 Gy), day 2 (25 µm; 211 ctc; 360 Gy), and day 3 (25 µm; 211 ctc; 400 Gy). This strategy increased the lifespan of the 9LGS-bearing rats by 216% in comparison to the control group.

MRT has also been tested on 9LGS in combination with different therapeutic agents. In a study by Régnard and colleagues \[[@B36-cancers-12-00527]\], MRT (25 µm; 200 ctc; 625 Gy peak-dose) was combined with direct intra-tumoral injection of the chemotherapeutic agents' Temozolomide, Cisplatin, or the contrast agent Gadolinium. Combining Temozolomide and Cisplatin with MRT did not improve survival. However, the concomitant administration of Gadolinium, as a result of radiation dose-enhancement, did. The antimitotic drug Chalcone JAI-51 (an inhibitor of tubulin polymerization) improved survival of 9LGS-bearing rats when combined with two orthogonally cross-fired MRT arrays (50 µm; 200ctc; 480 Gy peak-dose) \[[@B37-cancers-12-00527]\]. Furthermore, Sorafenib (an anti-angiogenic drug) was tested in combination with MRT on the same cancer model \[[@B38-cancers-12-00527]\]. Although the tumour growth rate was similar after MRT and the MRT+Sorafenib groups, there were appreciable changes in the tumour physiology which included reduced tumour blood volume after MRT+Sorafenib.

A study from 2006 shed light on the possible synergistic action between MRT and the immune system \[[@B39-cancers-12-00527]\] where combining MRT (27 µm; 211 ctc; 625 Gy peak-dose) with injections of irradiated 9LGS cells (transfected with the gene GM-CSF), increased the median survival of 9LGS-bearing rats.

Other types of glioma cell lines have also been exposed to MRT. F98 glioma cells and C6 cells, implanted respectively in Wistar and Fisher rats, were used to demonstrate that two orthogonal, cross-planar MRT arrays (24.75 µm; 211 ctc; 350 Gy peak-dose) significantly increased survival as compared to untreated controls \[[@B40-cancers-12-00527]\]. This effect was amplified when MRT was preceded by the administration of the glutathione synthesis inhibitor buthionine-SR-sulfoximine \[[@B41-cancers-12-00527]\]. When two orthogonal MRTs (50 µm; 200 ctc; 241 Gy peak-dose and 10.5 Gy valley-dose) were compared to two orthogonal BB fields (10.5 Gy), MRT was more effective than BB in slowing F98 glioma growth and increasing tumour vessel permeability \[[@B42-cancers-12-00527]\]. The same model of F98 cells in rats was employed by Fernandez-Palomo and colleagues, to prove that the presence of glioma causes different abscopal and bystander effects in MRT-irradiated rats and also in unirradiated (tumour-free) cage-mate rats \[[@B43-cancers-12-00527]\].

C6 glioma-bearing rats were also employed by Fernandez-Palomo et al. for the study of bystander and abscopal effects when comparing MRT with BB \[[@B19-cancers-12-00527]\]; both MRT and BB promoted radiation-induced bystander effects in the non-irradiated portion of the brain and in the bladder of the tumour-bearing animals. This same model has been used to study the dose deposition of MRT (25 μm; 200 ctc; at 35, 70 or 350 Gy peak-dose) using the marker of DNA damage 𝛾-H2AX \[[@B44-cancers-12-00527]\]. Moreover, the damage of the optic nerve was studied after treating the same C6 glioma in Wistar rat with cross-fired MRTs (25 μm; 200 ctc, 350 Gy peak-dose) \[[@B45-cancers-12-00527]\]. The optic nerves did not show any significant histological difference compared to unirradiated controls.

Rat xenografts of glioma cells implanted in the brain of nude mice were also used in MRT studies. In a model of 9LGS cells implanted in nude mice (strain not reported), a significant increase of tumoral apparent diffusion coefficient (ADC), consistent with an increase of vascular permeability, was shown 24 h after the delivery of two orthogonally cross-planar MRT arrays (25 μm; 211 ctc; 500 Gy peak-dose) in irradiated tumours versus unirradiated controls \[[@B46-cancers-12-00527]\]. In addition, athymic nude mice (Crl:NU-Foxn1nu) were implanted with F98 glioma cells to establish that bystander and abscopal effects can also be detected in athymic mice after MRT irradiation (50 μm; 200 ctc; 22 or 110 Gy peak-dose) \[[@B47-cancers-12-00527]\].

Finally, it must be mentioned that human xenografts in nude mice have also been explored. In the study performed by Uyama and colleagues \[[@B48-cancers-12-00527]\], U251 human glioma cells, implanted subcutaneously into the flank of nude mice (BALB/cAJc1-nu/nu), were employed to successfully demonstrate the efficacy of one MRT array (100 μm; 500 ctc; 124 Gy peak-dose) and two cross-planar, but unidirectional MRT arrays of (100 μm; 500 ctc; 124 Gy peak-dose) or (20 μm; 100 ctc; 111 Gy peak-dose) at the SPring-8 Synchrotron radiation facility in Japan.

### 3.4.3. Mammary Tumours {#sec3dot4dot3-cancers-12-00527}

Investigations of the effects of MRT on mammary malignancies have been made at the Japanese and Australian Synchrotrons. The most used pre-clinical model for the study of MRT on mammary malignancies is the subcutaneous injection of EMT-6.5 mouse mammary carcinoma cells in female BALB/c mice. Dilmanian and colleagues \[[@B49-cancers-12-00527]\] injected EMT6.5 cells subcutaneously in the flanks of mice from which tumours were subsequently harvested and small portions transplanted subcutaneously into the calves of BALB/c female mice. These mammary carcinoma-bearing mice were targeted with either one MRT array (90 μm; 300 ctc; doses in [Table 1](#cancers-12-00527-t001){ref-type="table"}), two cross-planar but unidirectional arrays (90 μm; 300 ctc; doses in [Table 1](#cancers-12-00527-t001){ref-type="table"}), or with BB of either 23, 30, 38, or 45 Gy. They reported that even one array can control EMT-6.5 tumour growth but that the cross-planar configuration optimally balances tumour control and tissue toxicity.

By subcutaneously inoculating EMT-6.5 and 67NR mammary tumour cells on the right hind leg of BALB/c mice, Crosbie and colleagues \[[@B50-cancers-12-00527]\] showed a significant increase in median survival compared to controls following one MRT array (25 μm; 200 ctc, 560 Gy). They also showed no signs of tumour re-growth after two different cross-fired MRT arrays (25 μm; 200 ctc; 280 Gy peak-dose) and (25 μm; 200 ctc; 560 Gy peak-dose).

Using the same syngeneic model, a comprehensive transcriptomic analysis of EMT-6.5 tumours, exposed either to MRT (25 μm; 200 ctc; 560 Gy peak-dose) or BB (11 or 22 Gy) compared to non-irradiated tumour controls, underlined how MRT-treated tumours overexpress immune-related genes at early time points after irradiation \[[@B51-cancers-12-00527]\]. Similarly, MRT (25 μm; 200 ctc; 112 Gy or 560 Gy peak-dose) delivered to EMT-6.5 tumours up-regulated genes that are involved in eosinophil recruitment and/or functionality relative to BB (5 or 9 Gy) irradiated tumours \[[@B52-cancers-12-00527]\]. Using the same EMT-6.5 mouse model and same MRT and BB configurations and doses, Yang et al. \[[@B53-cancers-12-00527]\] showed that a different immune response is induced by MRT compared to BB, including a significant increase of tumour-infiltrating T-lymphocytes at 48h post-MRT.

The tissue composition of the EMT6.5 mammary model was investigated after MRT (25 μm; 200 ctc; 560 Gy peak-dose) and BB (11, 22 or 44 Gy) using Fourier-transform infrared microspectroscopy \[[@B54-cancers-12-00527]\]. Absorbance patterns in the nucleic acid region showed chemical shifts between the peak and valley-dose regions \[[@B54-cancers-12-00527]\].

Griffin et al. \[[@B55-cancers-12-00527]\] employed a different type of syngeneic mouse model of mammary carcinoma, where 4T1 cells were injected subcutaneously in the limb of female BALB/c mice. They combined MRT with the anti-angiogenic peptide anginex and showed enhanced tumour growth-delay in combination with MRT.

### 3.4.4. Melanoma {#sec3dot4dot4-cancers-12-00527}

A recent publication from Potez et al. \[[@B7-cancers-12-00527]\] described for the first time that MRT (50 μm; 200 ctc; 407.6 Gy peak-dose) is an efficient approach for the treatment of radioresistant melanomas compared to a BB (6.2 Gy) irradiation and unirradiated control animals. In this model, B16-F10 melanoma cells were implanted in the ears of C57BL/6J mice.

### 3.4.5. Squamous Cell Carcinoma {#sec3dot4dot5-cancers-12-00527}

One study from Miura and colleagues \[[@B56-cancers-12-00527]\] employed a murine model of aggressive murine SCCVII squamous cell carcinomas implanted subcutaneously into the left thighs of female C3H mice. They showed that a better palliative effect was elicited by MRT irradiations (35 μm; 200 ctc; 625 Gy or 884 Gy peak-dose and 70 μm; 200 ctc; 442 Gy peak-dose) compared to BB (25 or 35 Gy) irradiations.

### 3.4.6. MRT for non-neoplastic diseases {#sec3dot4dot6-cancers-12-00527}

Microbeam radiation therapy has also been applied to the treatment of several non-malignant diseases and employed as a tool for studying Central Nervous System (CNS) injury.

#### Epilepsy:

Due to the high tolerance of the central nervous system to MRT, it has been applied, pre-clinically, as a radio-surgical tool to modulate brain networks and treat a variety of neurological disorders including epilepsy. The size and precision of microbeams can mimic a surgical cut to the epileptic cortex reproducing the current surgical ablation techniques but with a reduced risk of inducing neurological dysfunction \[[@B57-cancers-12-00527],[@B58-cancers-12-00527]\]. Microbeam transections of the sensorimotor cortex significantly reduced seizure without inducing neurological dysfunction (100 μm; 400 ctc; 240 or 320 Gy peak-dose) \[[@B59-cancers-12-00527]\]. This is reflected by decreased neuronal excitability of neurons in the somatosensory cortex and reduction of spontaneous synaptic activities and synchronization \[[@B60-cancers-12-00527]\]. Anti-epileptic activity was maintained more than 4 months post-irradiation \[[@B61-cancers-12-00527]\] with an absence of myelin and neurons in the microbeam-irradiated slices \[[@B62-cancers-12-00527]\].

#### Restenosis:

MRT has been implemented as a potential treatment for restenosis following angioplasty, exploiting the vascular-sparing and wound-healing effects of MRT to interfere with the process of cellular hyperplasia, which underlies this condition \[[@B63-cancers-12-00527]\]. The MRT array used in this study (27 μm; 200 ctc; 150 Gy peak-dose) did not yield significant improvement, and future dose-escalation studies are required.

#### Spinal cord Injury:

MRT has also been used as a tool to induce spinal cord injuries to study the mechanisms following CNS injury \[[@B64-cancers-12-00527]\]. Further studies have been performed, but their microbeams width fall outside our inclusion criteria.

### 3.4.7. Normal Tissue Effects of MRT {#sec3dot4dot7-cancers-12-00527}

It has been well described that in addition to effective tumour control, MRT exhibits exceptional preservation of normal tissues. This tissue-sparing effect is exemplified by the high tolerance of skin, CNS, and vasculature following MRT doses. [Table 2](#cancers-12-00527-t002){ref-type="table"} provides a summary of the conservative MRT parameters that each publication cites before the onset of pathology in the majority of test animals. Valley-doses are indicated where provided.

#### Central Nervous System, Adults:

Slatkin et al. 1995 presented the tissue-sparing effects on normal adult rat brain exposed to MRT (20 μm; 200 ctc) \[[@B18-cancers-12-00527]\]. Brain tissue appeared normal following peak-dose of 625 Gy, necrosis was absent even after peak-doses of up to 5000 Gy, and was visible only after a peak-dose of 10000 Gy. In another study, when multiple arrays were used, brain tissue damage was restricted to the cross-irradiated regions of the two arrays (25 μm; 200 ctc; 625 Gy peak-dose) and normal tissue damage was absent in the brain exposed to only one array \[[@B25-cancers-12-00527]\]. Irradiation of the rat spinal cord did not impair locomotion after 253 Gy (35 μm; 210 ctc), while paresis and foreleg paralysis developed when the dose reached 357 Gy or greater \[[@B65-cancers-12-00527]\]. When valley-doses at the target depth approached 18 Gy (507 Gy peak-dose), white and grey matter necrosis, necrosis of microvasculature and leukocyte infiltration was observed.

#### Developing CNS:

Employing MRT in infant patients was also pursued in pre-clinical studies. Early MRT studies were aimed at assessing its effects on immature brain tissues with suckling rats \[[@B26-cancers-12-00527]\], weanling piglets \[[@B66-cancers-12-00527]\] and unhatched duck embryos \[[@B67-cancers-12-00527]\] as models. In fact, there was a differential dose tolerance of the suckling rat relative to the weanling piglet, with the rat displaying neurological dysfunction when exposed to 150 Gy (28 μm; 105 ctc)\[[@B26-cancers-12-00527]\]. Similarly, irradiation of the CNS of the unhatched duck embryo could withstand a peak-entrance dose of 160 Gy (27 μm; 100 ctc) before displaying signs of ataxia within 75 days of hatching \[[@B67-cancers-12-00527]\]. In contrast, the piglet showed no signs of neurological damage at an dose of 600 Gy (28-30 μm; 200 ctc) \[[@B66-cancers-12-00527]\]. These three studies had comparable beam widths, however, they differed in the beam spacing with 100 μm and 200 μm used in the rat and piglet, respectively. When the spacing was increased to 200 μm, the dose threshold tolerated by the suckling rat increased to 300 Gy without signs of neurological dysfunction \[[@B26-cancers-12-00527]\].

#### Eye:

Certain target areas in the brain may result in ocular radiation exposure. The eye of the rat developed retinal degeneration after bidirectional MRT arrays (25 μm; 211 ctc; 350 Gy peak-dose) \[[@B68-cancers-12-00527]\]. This may occur after exposure of the retina to valley doses of up to 14 Gy \[[@B69-cancers-12-00527]\]. The optic nerve was also preserved at these doses \[[@B45-cancers-12-00527]\], however, ocular damage following MRT irradiations to the brain have not been assessed at doses below 350 Gy. Therefore, a tolerance threshold cannot be reported.

#### Vasculature:

The normal tissue response and tissue sparing effect of MRT are dependent on the preservation or regeneration of microvasculature. Vasculature organization of the irradiated tissue depends on the stage of tissue maturation and as a result, determines tolerance to MRT. Models of immature vasculature have been the regenerating fin of the zebrafish \[[@B70-cancers-12-00527]\] and the early chick chorioallantoic membrane \[[@B71-cancers-12-00527]\]. The susceptibility of immature vessels to MRT-induced damage is significantly higher than the mature vessels which show very little post-MRT alterations (vascular lesions, reduced perfusion) when the MRT spacing is kept below 200 µm \[[@B71-cancers-12-00527]\]. Although conducted in non-malignant tissue, the immature vasculature is representative of the disorganized, leaky and fast-growing tumour vessel networks.

In the mouse brain, it has been shown that the microvasculature can withstand up to a 1000 Gy peak entrance dose from a unidirectional MRT array (25 μm; 211 ctc) \[[@B72-cancers-12-00527]\] with only transient blood-brain-barrier leakage. No vascular damage \[[@B73-cancers-12-00527]\], or changes in cerebral water content were observed at this dose \[[@B72-cancers-12-00527],[@B74-cancers-12-00527]\]. In the beam path, there is a progressive disappearance of glial and neuronal cells, but endothelial cells remain detectable in the irradiated tissue and tissue remains perfused. No changes in blood volume or vascular density are observed (up to 3 months post-irradiation) indicating rapid vascular repair \[[@B72-cancers-12-00527]\]. Additionally, peripheral arteries in the mouse can tolerate peak microbeam doses up to 2000 Gy (50 μm; 400 ctc) with minimal damage \[[@B75-cancers-12-00527]\].

#### Skin:

Studies investigating the tolerance of the skin of rats and mice have shown that doses up to 1170 Gy (90 μm; 300 ctc; dose-valley up to 35 Gy) are marked by the absence of moist desquamation, focal denudation or exudation \[[@B76-cancers-12-00527]\]. Moreover, 1740--1900 Gy peak-entry-doses showed significant damage to the skin in both the mouse and the rat with the development of moist desquamation, epilation, and necrosis. The valley-dose was responsible for these adverse reactions, limiting valley-doses to less than 45 Gy for both cross-planar MRT of 2 arrays \[[@B49-cancers-12-00527]\] and a single MRT array \[[@B76-cancers-12-00527]\]. The peak threshold dose is reduced to 650 Gy with a bidirectional microbeam as the volume of irradiated tissue is increased with this irradiation geometry. The skin has been shown to efficiently repair double-strand breaks in the microbeam path (24-84 hrs post-irradiation \[pi\]) with the absence of apoptosis after MRT (25 μm; 175 ctc) \[[@B77-cancers-12-00527]\]. Doses up to 800 Gy (25 μm; 200 ctc) exhibited similar damage to BB doses of up to 44 Gy \[[@B78-cancers-12-00527]\]. Histological changes following 800 Gy (25 μm or 50 μm; 200 ctc) include thickening of the dermis and epidermis, hyperkeratosis, dermal oedema, and a loss of sebaceous glands \[[@B6-cancers-12-00527],[@B78-cancers-12-00527]\].

#### Other tissues:

Lastly, MRT has been applied as a fertility-sparing modality for testicular irradiation and has been able to successfully preserve spermatogenesis in the rat \[[@B79-cancers-12-00527]\]. MRT could, therefore, also be implemented as a treatment modality for testicular cancers or tumours in the inguinal region where infertility is an adverse outcome of current conventional radiotherapies.

#### Importance of Valley-Doses:

Normal brain tissue damage (including radiation-induced necrosis) is highly dependent on the valley-dose, and many authors suggest that cells in these regions repopulate the tissue damage in those regions receiving the peak-dose \[[@B25-cancers-12-00527],[@B49-cancers-12-00527],[@B66-cancers-12-00527],[@B73-cancers-12-00527],[@B80-cancers-12-00527],[@B81-cancers-12-00527]\]. Therefore, it is important to ensure that valley-dose does not exceed the tolerance threshold of the normal tissue \[[@B65-cancers-12-00527]\]. Valley-doses can be reduced either by decreasing the peak-dose, decreasing the width of the microbeam itself or decreasing the beam field-size \[[@B34-cancers-12-00527]\]. Delivered MRT doses attenuate with increasing tissue depth \[[@B34-cancers-12-00527]\], with the peak regions exhibiting a sharper fall-off than the valley regions \[[@B82-cancers-12-00527]\].Ensuring effective dose delivery to the target while maintaining appropriate valley-doses to preserve normal tissue, is therefore an essential step in treatment planning. Many papers in the MRT field do not report predicted doses received by the target tissue, but when provided, these values are reported in [Table 2](#cancers-12-00527-t002){ref-type="table"}.

4. Discussion {#sec4-cancers-12-00527}
=============

Conventional RT aims to cure cancer by directly ablating tumorous while selectively sparing healthy tissues. All modern RT modalities and techniques, ranging from high energy photons to proton and carbon ions, follow the same paradigm of directly destroying malignant tissue. However, their success is limited by radiation-induced toxicity to surrounding healthy tissue. This is especially critical in radiation-resistant tumours, where high, local doses are required for tumour control. MRT, however, targets tumours and the tumour microenvironment based on a different radiobiological paradigm (spatial fractionation). Thus, even tumour cells not directly irradiated can be eradicated completely while damage to healthy tissue can be repaired efficiently. As a consequence, it is anticipated that MRT will warrant higher tumour control at reduced toxicity in patients.

4.1. Potential Underlying Mechanisms of Microbeam Radiation Therapy {#sec4dot1-cancers-12-00527}
-------------------------------------------------------------------

### 4.1.1. Targeted and Non-Targeted Effects of MRT {#sec4dot1dot1-cancers-12-00527}

Peak-doses cause severe radiation damage that is restricted to the cell populations in the path of the microbeam. This can be observed in the brain of rats as early as 8h post MRT (25 μm; 200 ctc; 350 Gy peak-dose) \[[@B44-cancers-12-00527]\], and as late as 128 days post MRT (25 μm; 100 ctc; 625 Gy peak-dose) \[[@B25-cancers-12-00527]\]. In the cerebellum of piglets, microbeam tracks were still visible 15 months post MRT (20--25 μm; 211 ctc; cerebellar peak-dose 66 to 263 Gy; valley-dose 3.2 to 12.6 Gy) \[[@B66-cancers-12-00527]\]. Sharp delimitation of damaged tissue in the microbeam path has also been shown in *Drosophila* tissue where high peak doses exceeding lethal, seamless irradiation doses affect specific morphological processes while maintaining the survival of post-mitotic tissues and the organism as a whole \[[@B84-cancers-12-00527]\].

Radiation-induced bystander effects (RIBE) are relevant for MRT because tissue exposed to the valley-dose will receive signals from neighbouring cells exposed to the peak-dose. Although falling outside of our inclusion criteria due to its employment of a single microbeam and not an array, Dilmanian et al \[[@B85-cancers-12-00527]\] were the first to suggest the importance of RIBE in MRT. Their results from irradiated rat spinal cord indicated that the repair process and the elimination of apoptotic cells in the peak area occurred faster than expected, suggesting that restoration and proliferation was a consequence of "beneficial" bystander factors coming from the valley area. This was further suggested by the results of experiments by Fernandez-Palomo et al \[[@B44-cancers-12-00527]\] performed in the brain of rats.

When it comes to the effects on non-irradiated tissues (outside of the microbeam array), responses such as genotoxic effects \[[@B77-cancers-12-00527]\] and clonogenic cell death on cells exposed to signals from the irradiated animal \[[@B19-cancers-12-00527],[@B43-cancers-12-00527]\] have been observed after MRT. Some of those responses have involved the immune system \[[@B47-cancers-12-00527]\], with some author suggesting that a functional immune system is key to observe such genotoxic effects post MRT \[[@B86-cancers-12-00527]\].

### 4.1.2. MRT Selectively Disrupts Immature Blood Vessel {#sec4dot1dot2-cancers-12-00527}

The biological effects induced by MRT go beyond direct tumour cell destruction. In fact, MRT does not impact the morphological and functional characteristics of normal murine brain vessels even after delivery of doses up to 1000 Gy \[[@B72-cancers-12-00527]\]. Brain perfusion, capillary density and blood volume remain unaffected 12h to 3 months after an anteroposterior MRT array (25 μm; 211 ctc; 312 or 1000 Gy peak-entrance dose) \[[@B72-cancers-12-00527]\]. No changes in animal behaviour have been observed \[[@B72-cancers-12-00527]\]. Data from chick chorioallantoic membrane \[[@B71-cancers-12-00527]\] and zebrafish fin regeneration \[[@B70-cancers-12-00527]\] models demonstrate the disruptive vascular effect of MRT on immature blood vessels. Work in adult organisms confirmed that the disruptive vascular effects of MRT depend on the vascular maturation status. In adult zebrafish, a correlation between microbeam width and biological effects of MRT was identified \[[@B70-cancers-12-00527]\]. The study indicated that microbeam spacing between 50 to 100 µm could selectively affect mature and immature vessels. Murine brain vessels do not tolerate beamlets wider than 100µm when peak doses of 400 Gy are delivered \[[@B87-cancers-12-00527]\]. The use of MRT in rodent models revealed a preferential adverse effect on tumour vessels rather than those of healthy tissue. In a murine melanoma model, MRT significantly reduced (24%) the perfusion of the tumour blood vessels indicating vascular disruption \[[@B7-cancers-12-00527]\].

MRT preferentially lowers tumour O~2~ saturation levels in gliosarcoma as a result of reduced endothelial cell density and increased inter-vessel distance following two cross-fired arrays (anteroposterior and lateral; each 50 μm; 200 ctc; 400 Gy peak-entry-dose) leading to tumour hypoxia observed by GLUT-1 overexpression \[[@B32-cancers-12-00527],[@B33-cancers-12-00527],[@B38-cancers-12-00527]\]. However, the persistence of hypoxia may be dose-, time- and tumour-dependant with contrasting evidence of tumour hypoxia in a mammary carcinoma decreasing within 14 days post-irradiation at a dose of 150 Gy \[[@B55-cancers-12-00527]\].

### 4.1.3. MRT Transiently Increases Tumour Blood Vessel Permeability {#sec4dot1dot3-cancers-12-00527}

Few reports indicate that MRT causes a partial disintegration of the endothelium leading to an early (1 to 4h) but significant increase in tumour blood vessel permeability (manuscript in preparation). This "MRT-induced vascular permeability window" represents a potent drug delivery strategy. Combination of MRT with chemotherapy or nanoparticles applied in the "permeability window" results in significantly better tumour control (manuscript in preparation). A recently published study indicated that MRT induced selective vascular permeability in tumour blood vessels but not in normal vasculature. The tumour vascular permeability was observed from days 2 to 7 after MRT. In contrast, it was observed only at day 7 after BB radiotherapy \[[@B42-cancers-12-00527]\]. This study also documented that delivering a second MRT array induced earlier, more pronounced, and more persistent tumour vascular permeability than BB.

### 4.1.4. MRT Boosts the Recruitment of Circulating Immune Cells into Tumours {#sec4dot1dot4-cancers-12-00527}

Data obtained in zebrafish indicate that MRT triggers an acute inflammatory response restricted to the regenerating tissue \[[@B70-cancers-12-00527]\]. Six hours post-MRT, the regenerating tissue was infiltrated by neutrophils, and thrombocytes which adhered to the cell wall locally in the beam path. The mature tissue was not affected by microbeam irradiation \[[@B70-cancers-12-00527]\]. In a mouse tumour model, it has been demonstrated that BB markedly increases tumour-associated macrophages and neutrophils while there were no increases in these populations following MRT \[[@B53-cancers-12-00527]\]. The role of MRT in the recruitment of immune cells represents a promising immunoprophylactic treatment strategy and should be further explored in experimental and clinical studies. A recently performed study in melanoma-bearing animals showed that MRT (particularly after 2 irradiations) selectively increased production of natural killer (NK) cell- and cytotoxic T lymphocytes-attracting chemokines while, also showing, decreased secretion of T regulatory cell-, tumour associated macrophage- and neutrophil-recruiting chemokines (manuscript in review). The role of single and repeated MRT administration in the recruitment of immune cells represents a promising immunoprophylactic treatment strategy and should be further explored in experimental and clinical studies.

In addition, increased pericyte density following MRT suggests a vascular normalization effect \[[@B55-cancers-12-00527]\] which may increase migration of immune cell populations to the tumour and modulate cytokine expression that may support an anti-tumour immune response. Synergism between immunoprophylaxis and MRT has been documented \[[@B39-cancers-12-00527]\]. Differential modulation of genes involved in inflammation and immunity are also marked at early timepoints between tumour and normal tissue \[[@B29-cancers-12-00527],[@B52-cancers-12-00527]\] and increased leukocyte infiltration into the tumour has also been observed.

4.2. Clinical Translation {#sec4dot2-cancers-12-00527}
-------------------------

Barriers to the translation of MRT relate to a limited understanding of how to compare the radiobiological effects of MRT with conventional BB radiotherapy, as well as, understanding the biology behind the physical properties of the microbeams. In addition, the optimal therapeutic strategy for MRT is still to be defined.

### 4.2.1. Comparative Therapeutic Effects of MRT and BB Radiotherapy {#sec4dot2dot1-cancers-12-00527}

A limited number of studies systematically compared the biological effects of MRT with BB radiotherapy. The superiority of MRT compared to synchrotron BB treatment for tumour control has been demonstrated in mice bearing B16-F10 melanoma \[[@B7-cancers-12-00527]\] and rats bearing 9LGS \[[@B31-cancers-12-00527]\]. In these studies, the MRT valley-dose was kept equal to the BB dose; however, future studies could use the Equivalent Uniform Dose concept (EUD) to determine more biologically comparable doses of MRT and BB \[[@B88-cancers-12-00527]\].

Dose-escalation studies in healthy rodents have identified doses of MRT and BB predicted to cause equal rates of late spinal cord myelopathy \[[@B65-cancers-12-00527]\], lethal neurotoxicity \[[@B80-cancers-12-00527]\] and acute toxicity following total and partial body irradiation \[[@B83-cancers-12-00527]\]. Of these studies, only Smyth et al. \[[@B83-cancers-12-00527]\] included a comparison between MRT and BB radiotherapy at a conventional dose-rate (in the order of 2 Gy min^−1^). This indicates the need for further studies controlling for the potential FLASH tissue-sparing effects of synchrotron broad-beam irradiation.

### 4.2.2. Identifying Optimal Targets and Strategies for MRT {#sec4dot2dot2-cancers-12-00527}

A key limitation of MRT is the need for a kilovoltage energy spectrum to maintain spatial fractionation on a microscopic scale, leading to 30--40% of the dose being attenuated within the first few centimetres of tissue \[[@B89-cancers-12-00527],[@B90-cancers-12-00527]\]. In addition, the PVDR, which is a metric intrinsically linked to the therapeutic ratio of MRT, decreases with increasing tissue depth and field size \[[@B89-cancers-12-00527]\]. The majority of pre-clinical studies to date have been performed in rodent models ([Figure 3](#cancers-12-00527-f003){ref-type="fig"}), where this issue of beam penetration and PVDR is less important due to the small dimensions of the target. However, human diseases will require larger field sizes and target depths \[[@B91-cancers-12-00527]\].

Given that PVDRs are likely to be lower for human treatments \[[@B91-cancers-12-00527]\], a strategy which relies on relatively low peak-dose (100--250 Gy) by leveraging the immunomodulatory \[[@B29-cancers-12-00527],[@B53-cancers-12-00527]\] or angio-disruptive effects of MRT \[[@B42-cancers-12-00527],[@B70-cancers-12-00527]\] could strike an optimal balance between toxicity and tumour control. Previous studies have shown MRT to be effective for treating rat models of glioma when combined with chemotherapeutic agents \[[@B36-cancers-12-00527],[@B37-cancers-12-00527],[@B41-cancers-12-00527]\] or immunotherapy \[[@B39-cancers-12-00527]\]. Future studies should investigate the optimal dose, sequencing and timing of MRT in relation to chemotherapy and immunotherapy and whether there is a role for temporally fractionating the delivery of MRT. This is particularly relevant for combined radio-immunotherapy, where fractionated radiotherapy has been shown to be more effective than a large single fraction for stimulating an immunogenic response \[[@B92-cancers-12-00527],[@B93-cancers-12-00527]\]. The combination of MRT with immunotherapy is an under-explored frontier which warrants the attention of future pre-clinical studies. A previously established model of metastatic melanoma \[[@B7-cancers-12-00527]\] could be ideal in this context, given the clinical use of radio-immunotherapy for melanoma.

### 4.2.3. Candidate Animal Models {#sec4dot2dot3-cancers-12-00527}

Animal models for future research should reflect technically feasible and medically justifiable clinical scenarios for a human trial of MRT. Although various brain malignancies have been the major focus of pre-clinical MRT research and proposed as future targets for clinical MRT \[[@B94-cancers-12-00527],[@B95-cancers-12-00527],[@B96-cancers-12-00527]\], the depth of intracranial diseases, the need for beams to transverse the skull, and the potential proximity to sensitive structures could make it a difficult target for the first clinical trials. However, lessons can be learned from the relatively newer field of FLASH radiotherapy which has already been translated to the clinic with the first human FLASH treatment being for cutaneous T-cell lymphoma on the forearm \[[@B22-cancers-12-00527]\].

Similarly, superficial or cutaneous lesions, as well as those of the appendicular musculoskeletal system \[[@B96-cancers-12-00527]\], would be ideal candidates for the first human trials of MRT. Therefore, future animal models for MRT research could include murine models of cutaneous T-cell lymphoma \[[@B97-cancers-12-00527],[@B98-cancers-12-00527],[@B99-cancers-12-00527]\], locally recurrent breast cancer \[[@B100-cancers-12-00527]\], soft-tissue sarcoma \[[@B101-cancers-12-00527],[@B102-cancers-12-00527]\] and osteosarcoma \[[@B103-cancers-12-00527],[@B104-cancers-12-00527],[@B105-cancers-12-00527]\]. These are diseases which can be highly radio-resistant and are often refractory to conventional radiotherapy. Ideally, murine models should be immunocompetent in order to explore and harness the immunomodulatory effects of MRT. Furthermore, soft-tissue sarcoma and osteosarcoma occur spontaneously in canines and are well-established models of human disease \[[@B106-cancers-12-00527],[@B107-cancers-12-00527]\]. Veterinary patients would be on a size and scale more comparable to humans and could provide an intermediate step towards a clinical trial.

4.3. Limitations of this Study {#sec4dot3-cancers-12-00527}
------------------------------

A limitation of this study was that some articles, whose sole purpose was studying the effects of MRT, fell outside our inclusion criteria because the researchers used a single beam instead of an array. We would like to report that in one case (properly informed in the text of this scoping review), we cited one of these articles to complement other animal studies in MRT.

5. Conclusion and Recommendations {#sec5-cancers-12-00527}
=================================

5.1. Appropriate Controls {#sec5dot1-cancers-12-00527}
-------------------------

Historically the dose delivered by a synchrotron BB has been considered as a control for MRT. However, BB originating from synchrotron sources has the potential of achieving FLASH normal tissue sparing effect. Therefore, the therapeutic advantages of MRT over BB may have been substantially underestimated in these studies, and appropriate BB irradiation controls, using conventional dose-rates from clinical linear accelerators or conventional kilovoltage X-ray sources should be used. Additionally, comparative doses should be based on biological equivalence, such as Equivalent Uniform Dose, rather than valley-dose alone.

5.2. Standardization of the MRT Array and Doses {#sec5dot2-cancers-12-00527}
-----------------------------------------------

Amongst the literature, there is a wide variation in the parameters used for the MRT array and peak and valley-doses. We recommend working on establishing a method for tracking and standardizing the effects of these variations. We hope that the two tables presented in this scoping review can serve as a starting point when selecting radiation parameters for future studies. So that effective tumour control with effective normal tissue sparing can be achieved. Moreover, progress is needed to identify the optimal MRT array and doses required for adequate vascular disruption, vascular permeability and recruitment of tumour-infiltrating immune cells in each animal model.

5.3. Preclinical Animal Models {#sec5dot3-cancers-12-00527}
------------------------------

The most employed tumour models, especially for brain tumours, have been established in rats. We recommend diversifying the use of animal species and including new tumour cancer models to accelerate the clinical translation of MRT.

5.4. Veterinary Trials {#sec5dot4-cancers-12-00527}
----------------------

Veterinary trials, in canines or felines, will provide an important intermediary step between small, pre-clinical animal models and human treatments. These trials will be crucial to ensure the radiobiology and physical characteristics of MRT can be translated to humans despite the challenges of size and beam attenuation. Furthermore, large animal models will validate a clinical workflow for MRT, including custom dose-calculation algorithms, conformal treatment planning capabilities, image-guidance, patient-positioning systems, and reporting and verification of dose coverage of the target. At this stage, superficial lesions of extremities are the likely first candidates for veterinary trials, considering their current use in translational research, their prevalence in the canine population and a favourable anatomic location and depth for MRT.

We believe that the consolidation of these five recommendations may result in a significant advance and rapid adoption of MRT in the clinic.

We dedicate this review to our dear colleague Elke Bräuer-Krisch who was an integral part of MRT research and a proponent for its clinical application. We would also like to thank the MRT community for all the helpful and stimulating discussions.

The detailed Search Strategy and the list of the 95 included articles can be found at <https://www.mdpi.com/2072-6694/12/3/527/s1>.
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![Homogenous radiation vs spatial fractionation. Schematic representation of a homogenous beam of radiation (panel **A**) and a MRT array (panel **B**) targeting a malignancy. Schematic representation of the microbeams dose distribution (panel **C**).](cancers-12-00527-g001){#cancers-12-00527-f001}
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###### 

MRT Parameters Used in Cancer Models.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Animal                                   Cancer Type                             Number of Arrays        Microbeam           Peak-dose (Gy)     Valley-dose (Gy)                            Evaluated Criteria                       
  ---------------------------------------- --------------------------------------- ----------------------- ------------------- ------------------ ------------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------
  Rat \[[@B1-cancers-12-00527]\]           Gliosarcoma (9L)                        1 & 2                   50                  200                400 entrance dose;\                         12.5 \@1cm depth                         Animal survival, tumour growth, tumour vasculature, and cell proliferation
                                                                                                                                                  350 \@1cm depth                                                                      

  Rat \[[@B2-cancers-12-00527]\]           Gliosarcoma (9L)                        2                       50                  200                480 entrance dose;\                         18.6 \@1cm depth                         Animal survival, cell cycle, and DNA distribution patterns
                                                                                                                                                  418 \@1cm depth                                                                      

  Rat \[[@B3-cancers-12-00527]\]           Gliosarcoma (9L)                        2                       50                  200                400 entrance dose;\                         12.5 \@1cm depth                         Tumour vasculature and tumour oxygenation
                                                                                                                                                  350 \@1cm depth                                                                      

  Rat \[[@B4-cancers-12-00527]\]           Gliosarcoma (9L)                        1                       50                  200                400 dose \@tumour\                          18 dose \@tumour (i.e., \@7mm depth)     Animal survival and Transcriptomics
                                                                                                                                                  (i.e., \@7mm depth)                                                                  

  Rat \[[@B5-cancers-12-00527]\]           Gliosarcoma (9L)                        1                       50                  200                400 dose \@tumour\                          8 dose \@tumour (i.e., \@7mm depth)      Tumour growth, transcriptomics, and histopathology
                                                                                                                                                  (i.e., \@7mm depth)                                                                  

  Rat \[[@B6-cancers-12-00527]\]           Gliosarcoma (9L)                        1                       50                  200                400 dose \@tumour\                          17.4 dose \@tumour (i.e., \@7mm depth)   Animal survival, tumour growth, cell proliferation, and gene expression
                                                                                                                                                  (i.e., \@7mm depth)                                                                  

  200 dose \@tumour (i.e., \@7mm depth)    8.7 dose \@tumour (i.e., \@7mm depth)                                                                                                                                                       

  Rat \[[@B7-cancers-12-00527]\]           Glioma (F98)                            2                       50                  200                241.4 entrance dose                         10.5 \@9mm depth                         Tumour vasculature and tumour oxygenation

  Mouse \[[@B8-cancers-12-00527]\]         Mammary (EMT6.5/67NR)                   1                       25                  200                560 entrance dose                           8.5 \@centre of brain                    Animal survival, DNA damage, cell proliferation, and apoptosis

  800 entrance dose                        12 \@centre of brain                                                                                                                                                                        

  2                                        280 entrance dose                       8.5 \@centre of brain                                                                                                                               

  560 entrance dose                        17 \@centre of brain                                                                                                                                                                        

  Rat \[[@B9-cancers-12-00527]\]           Gliosarcoma (9L)                        1                       27                  50                 150 entrance dose;\                         20 \@centre of brain                     Animal survival and histopathology
                                                                                                                                                  108 \@centre of brain                                                                

  250 entrance dose;\                      34 \@centre of brain                                                                                                                                                                        
  179 \@centre of brain                                                                                                                                                                                                                

  300 entrance dose;\                      40 \@centre of brain                                                                                                                                                                        
  215 \@centre of brain                                                                                                                                                                                                                

  75                                       250 entrance dose;\                     17 \@centre of brain                                                                                                                                
                                           179 \@centre of brain                                                                                                                                                                       

  300 entrance dose;\                      20 \@centre of brain                                                                                                                                                                        
  215 \@centre of brain                                                                                                                                                                                                                

  500 entrance dose;\                      33 \@centre of brain                                                                                                                                                                        
  359 \@centre of brain                                                                                                                                                                                                                

  100                                      500 entrance dose;\                     19 \@centre of brain                                                                                                                                
                                           359 \@centre of brain                                                                                                                                                                       

  Mouse \[[@B10-cancers-12-00527]\]        Mammary (EMT6.5)                        1                       90                  300                800 dose \@tumour                           16 dose \@tumour                         Tumour ablation

  890 dose \@tumour                        18 dose \@tumour                                                                                                                                                                            

  970 dose \@tumour                        19 dose \@tumour\                                                                                                                                                                           

  1740 dose \@tumour                       35 dose \@tumour                                                                                                                                                                            

  1820 dose \@tumour                       36 dose \@tumour                                                                                                                                                                            

  1900 dose \@tumour                       38 dose \@tumour                                                                                                                                                                            

  2                                        90                                      300                     410 dose \@tumour   16 dose \@tumour                                                                                        

  520 dose \@tumour                        21 dose \@tumour                                                                                                                                                                            

  650 dose \@tumour                        26 dose \@tumour                                                                                                                                                                            

  Rat \[[@B11-cancers-12-00527]\]          Glioma (C6)                             1                       25                  200                17.5, 35, 70, 350 entrance dose             0.51, 1.03, 2, 10.3                      Bystander effects in-vivo by clonogenic cell survival

  Rat \[[@B12-cancers-12-00527]\]          Glioma (C6)                             1                       25                  200                35, 70, 350 entrance dose                   NR                                       DNA damage

  Rat \[[@B13-cancers-12-00527]\]          Glioma (F98)                            1                       25                  200                20, 200 entrance dose                       NR                                       Bystander effects in-vivo by clonogenic cell survival and cellular calcium fluxes

  Mouse nude \[[@B14-cancers-12-00527]\]   Glioma (F98)                                                    50                  400                22, 110 entrance dose                       0.5, 2.5                                 Bystander effects in-vivo by clonogenic cell survival and cellular calcium fluxes

  Mouse \[[@B15-cancers-12-00527]\]        Mammary (4T1)                           1                       50                  200                150 \@5 mm depth                            7.5 in a 10 mm solid water\              Tumour growth, tumour vasculature, and tumour hypoxia
                                                                                                                                                                                              phantom                                  

  Mouse \[[@B16-cancers-12-00527]\]        Mammary (EMT6.5)                        1                       25                  200                112, 560                                    NR                                       Immune response by gene expression and histopathology

  Rat \[[@B17-cancers-12-00527]\]          Gliosarcoma (9L)                        1                       50                  200                400 entrance dose                           NR                                       Tumour vasculature, and tumour hypoxia

  Rat \[[@B18-cancers-12-00527]\]          Gliosarcoma (9L)                        1                       25                  100                625 entrance dose                           NR                                       Animal survival, tumour growth, and histopathology

  Mouse \[[@B19-cancers-12-00527]\]        Squamous cell carcinoma (SCCVII)        1                       35                  200                442, 625, 884 entrance dose                 NR                                       Animal survival, tumour growth, and tumour ablation

  70                                       200                                     442 entrance dose                                                                                                                                   

  Rat \[[@B20-cancers-12-00527]\]          Glioma (C6)                             2                       25                  200                350 entrance dose                           NR                                       Optic nerve damage by histopathology

  Mouse \[[@B21-cancers-12-00527]\]        Melanoma (B16F10)                       1                       50                  200                407.6 dose \@tumour                         6.2 dose \@tumour                        Tumour growth, tumour vasculature, cell proliferation, cell senescence, and immune response

  Rat \[[@B22-cancers-12-00527]\]          Gliosarcoma (9L)                        1                       25                  200                625 entrance dose                           12.1 dose \@tumour                       Animal survival, tumour growth, and histopathology

  100                                      625 entrance dose                       36 dose \@tumour                                                                                                                                    

  Rat \[[@B23-cancers-12-00527]\]          Gliosarcoma (9L)                        1                       25                  200                625 entrance dose                           NR                                       Animal survival, tumour growth, and histopathology

  Mouse \[[@B24-cancers-12-00527]\]        Mammary (EMT6.5)                        1                       25                  200                560 entrance dose                           11                                       Biochemical changes by synchrotron Fourier-transform infrared microspectroscopy

  Rat \[[@B25-cancers-12-00527]\]          Glioma (C6, F98)                        2                       25                  211                350 entrance dose                           NR                                       Animal survival and object recognition

  Rat \[[@B26-cancers-12-00527]\]          Glioma (F98)                            2                       28                  400                350                                         18 dose @ tumour                         Animal survival and cognitive dysfunction

  Mouse nude \[[@B27-cancers-12-00527]\]   Gliosarcoma (9L)                        1                       25                  211                500 entrance dose                           24 (cross-fired)                         Animal survival, tumour growth, and tumour vasculature

  Rat \[[@B28-cancers-12-00527]\]          Gliosarcoma (9L)                        2                       25                  211                860 entrance dose                           18 \@1cm depth                           Animal survival and histopathology

  50                                       480 entrance dose                                                                                                                                                                           

  75                                       320 entrance dose                                                                                                                                                                           

  Rat \[[@B29-cancers-12-00527]\]          Gliosarcoma (9L)                        3                       50                  211                400, 360 (+24h), 400 (+48h) entrance dose   15                                       Animal survival and histopathology

  Rat \[[@B30-cancers-12-00527]\]          Gliosarcoma (9L)                        1                       27                  211                625 entrance dose                           NR                                       Animal survival, histopathology, and immune response

  Mouse \[[@B31-cancers-12-00527]\]        Mammary (EMT6.5)                        1                       25                  200                560                                         11                                       Transcriptomics

  Mouse nude \[[@B32-cancers-12-00527]\]   Glioma (U251)                           1                       100                 500                124                                         4.8                                      Tumour growth, histopathology, and apoptosis

  2                                        20                                      100                     111                 8.2                                                                                                     

  100                                      500                                     124                     9.6                                                                                                                         

  Mouse \[[@B33-cancers-12-00527]\]        Mammary (EMT6.5)                        1                       25                  200                112, 560                                    NR                                       Immune response
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: Not-Reported.
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###### 

MRT Parameters Eliciting Normal Tissue Tolerance.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Animal                                             Tissue                                       Microbeam                        Pathology                    Threshold Peak-Dose (Gy)                                    Valley-Dose (Gy)              
  -------------------------------------------------- -------------------------------------------- -------------------------------- ---------------------------- ----------------------------------------------------------- ----------------------------- ------------------------------------
  Duck \[[@B67-cancers-12-00527]\]                   Immature CNS                                 27                               100                          Ataxia                                                      160                           NR

  Rat \[[@B15-cancers-12-00527]\]                    Brain                                        27                               75                           Necrosis, oedema                                            250                           17

  27                                                 100                                          500                              33                                                                                                                     

  Rat \[[@B73-cancers-12-00527]\]                    Brain                                        27                               200                          Cell loss, demyelination                                    1000                          NR

  Rat \[[@B25-cancers-12-00527]\]                    Brain                                        25                               100                          Tissue damage (loss of tissue structure; vascular damage)   625 uni- & bidirectional      NR

  312 bidirectional                                                                                                                                                                                                                                       

  Rat \[[@B65-cancers-12-00527]\]                    Spinal cord                                  35                               210                          Paresis/Paralysis (over 383 dpi)                            357 (19mm transverse depth)   12.7

  Mouse \[[@B72-cancers-12-00527]\]                  Brain                                        25                               211                          Damage to microvasculature/vasogenic oedema (up to 1 mpi)   312--1000                     5.8

  Rat (11--13 day old) \[[@B26-cancers-12-00527]\]   Brain                                        28                               105                          Neurological dysfunction                                    150                           \>5 Gy \[[@B69-cancers-12-00527]\]

  28                                                 105                                          50                                                                                                                                                      

  25                                                 210                                          300 bidirectional                                                                                                                                       

  Piglet \[[@B66-cancers-12-00527]\]                 Brain                                        20--30                           210                          Neurological function (465 dpi)                             600 peak-entry\               12.6 @ cerebellum
                                                                                                                                                                                                                            263 @ cerebellum              

  Rat \[[@B18-cancers-12-00527]\]                    Brain                                        20                               200                          Necrosis (14 dpi)                                           5000                          NR

  37                                                 75                                           Tissue damage (14--31dpi)        625                                                                                                                    

  20                                                 200                                          Loss of nuclei (30-31dpi)        2000                                                                                                                   

  37                                                 75                                                                                                                                                                                                   

  Skin                                               37                                           200                              Epilation (2--4 weeks dpi)   1250--2500                                                                                

  37                                                 75                                           1250--2500                                                                                                                                              

  Mouse \[[@B74-cancers-12-00527]\]                  Brain                                        25                               211                          Cerebral oedema (up to 28 dpi)                              \<1000                        10.5

  Mouse \[[@B49-cancers-12-00527]\]                  Skin                                         90                               300                          Moist desquamation                                          1740 co-planar                35

  650 cross-planar                                   26                                                                                                                                                                                                   

  Mouse \[[@B76-cancers-12-00527]\]                  Skin                                         90                               300                          Moist desquamation                                          1005-1170                     14-17

  Mouse \[[@B83-cancers-12-00527]\]                  Abdomen                                      25                               400                          GI syndrome                                                 249 (257 TD~50~)              7.5 (7.7)

  Head                                               Neurological dysfunction                     255 (268 TD~50~)                 6.8 (7.2)                                                                                                              

  Thorax                                             Neurological dysfunction, pulmonary damage   391 (lowest administered dose)   9.5                                                                                                                    

  Total body                                         Weight loss, moribund behaviour              88.9 (120 TD~50~)                2.8 (3.8)                                                                                                              

  Mouse \[[@B75-cancers-12-00527]\]                  Saphenous artery                             50                               400                          Functional deficits, atrophy, arterial damage               2000                          17.6

  Rat \[[@B34-cancers-12-00527]\]                    Brain                                        50                               211                          Neurological dysfunction                                    480                           18

  Mouse \[[@B79-cancers-12-00527]\]                  Testes (ex vivo)                             50                               100                          Spermatogenesis                                             5                             NR

  Rat \[[@B68-cancers-12-00527]\]                    Brain (+eye)                                 25                               211                          Retinal degeneration (12 dpi)                               350 \* (bidirectional)        NR

  Rat \[[@B45-cancers-12-00527]\]                    Brain (+eye)                                 25                               200                          Optic nerve damage                                          350 \* (bidirectional)        NR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Threshold Peak-Dose: indicates the highest peak-dose (skin entry or at indicated tissue depth) reported that did not result in pathology in the majority of animals. Note: studies testing only one dose are indicated by an asterisk (\*). NR: Not-Reported.
